Epicrispr Biotechnologies, Inc. — SEC Form D Filing
Epicrispr Biotechnologies, Inc. filed an SEC Form D on August 26, 2026, reporting $176.75M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 26, 2026
- Amount reported
- $176.75M
- Round stage
- Series C
- Industry
- Biotechnology
- Website
- https://epicrispr.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Complex diseases often arise from dysregulated gene expression and can have multiple genetic subtypes, making them challenging to treat effectively.
Solution
Epicrispr Biotechnologies is developing therapies using its Gene Expression Modulation System (GEMS) platform to precisely and dynamically control gene expression, aiming to treat complex diseases in a mutation-agnostic manner.
Verdict
Investors backed Epicrispr's Series C based on the promise of a platform technology addressing a fundamental biological challenge rather than a specific disease-market opportunity. They were implicitly betting on the GEMS platform's broad applicability and the team's ability to translate precise gene expression modulation into multiple clinically viable therapies. This cleared because the underlying science offered a novel mechanism to control disease, not because a clear, de-risked market entry point was articulated. The inherent complexity of developing platform-based therapeutics, coupled with regulatory uncertainty for novel modalities, limited immediate upside.
Source: SEC EDGAR Form D filing